The global anticoagulants market size is expected to reach $42,893.4 million by 2030, growing at a CAGR of 7.8% from 2021 to 2030.
The market is driven by the rising incidence of vascular diseases, such as heart attack, stroke, and pulmonary embolism. The market depends on R&D, and thus, patents provide opportunities to the players. Patents can give a competitive advantage to the manufacturer by granting a temporary monopoly and a certain period of market exclusivity. However, whenever a patent expires, drug prices fall dramatically. The extent to which the prices lower varies greatly between products and countries.
The injectable category will grow at the highest pace during the forecast period. Anticoagulants are widely administered intravenously (into a vein), deeply under the epidermis, and as a diluted solution, in the form of intravenous infusions.
The online pharmacies category is projected to witness the highest CAGR, of more than 8%, during the forecast period. This will be due to the growing popularity of online drug stores due to their ease and convenience of purchases.
Hospital pharmacies have also been one of the market's main contributors. This is due to the fact that the use of anticoagulants is highly risky and is frequently prescribed after a thorough diagnosis, which is often performed in healthcare facilities.
During the forecast period, the APAC anticoagulants market is expected to grow at the highest rate during the forecast period. This is because of its rising patient population suffering from cardiovascular diseases, such as coronary artery disease, DVTs, and heart attacks. The market has opportunities in developing economies due to the improving diagnosis rate and growing demand for ideal therapeutics. Furthermore, the continuous economic development, improvement in healthcare infrastructure, and rise in healthcare awareness are driving the market growth.
In terms of anticoagulants market revenue, Japan has a lucrative potential. With an aging population, there is a high demand for anticoagulants, as the elderly suffer from a number of illnesses, such as venous thromboembolism and atrial fibrillation. They also widely undergo knee and hip replacement surgeries, which increases the chances of their blood clotting, which can result in strokes and heart attacks. As a result, anticoagulant sales will increase in the future.
China is expected to have a sizable market share by 2030 due to the high incidence of chronic diseases. Anticoagulants are being advocated by healthcare providers in an effort to minimize the risk and burden of such ailments.
The market has the presence of several key players, who, in recent years, have been involved in various strategic developments in order to stay ahead of their competitors. For instance,
In December 2020, Natco Pharma launched Rivaroxaban, an anticoagulant drug that is now available in India under the brand name RPIGAT.
In November 2020, Bristol-Myers Squibb (BMS) finalized its $13.1-billion acquisition of MyoKardia, thus adding targeted cardiovascular clinical and pre-clinical treatments to its pipeline. The new product line comprises the anticoagulant Eliquis (apixaban) and the medication Opdivo (nivolumab).
Major players in the market are ASPEN PHARMACARE HOLDINGS LIMITED, Bayer AG, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, DAIICHI SANKYO COMPANY LIMITED, GlaxoSmithKline, Johnson & Johnson Services Inc., Pfizer Inc., and Sanofi.